The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
The therapeutic monoclonal antibody market
Open accessAbstract
Since the commercialization of the first therapeutic monoclonal antibody product in 1986, this class of biopharmaceutical products has grown significantly so that, as of November 10, 2014, forty-seven monoclonal antibody products have been approved in the US or Europe for the treatment of a variety of diseases, and many of these products have also been approved for other global markets. At the current approval rate of ∼ four new products per year, ∼ 70 monoclonal antibody products will be on the market by 2020, and combined world-wide sales will be nearly $125 billion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Production of recombinant protein therapeutics in cultivated mammalian cells
Wurm, F. M. (2004) · Nature Biotechnology · doi:10.1038/nbt1026 · Cited by 2,032
Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs
DiMasi, J. A., Feldman, L., Seckler, A., & Wilson, A. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.295 · Cited by 845
Human Development Report 2013: The Rise of the South - Human Progress in a Diverse World
United Nations Development Programme (2013) · Human Development Report · doi:10.18356/a1b0c169-en · Cited by 704
Recombinant protein therapeutics—success rates, market trends and values to 2010
Pavlou, A. K., & Reichert, J. M. (2004) · Nature Biotechnology · doi:10.1038/nbt1204-1513 · Cited by 334
High-throughput process development for biopharmaceutical drug substances
Bhambure, R., Kumar, K., & Rathore, A. S. (2011) · Trends in Biotechnology · doi:10.1016/j.tibtech.2010.12.001 · Cited by 177
Perfusion seed cultures improve biopharmaceutical fed‐batch production capacity and product quality
Yang, W. C., Lü, J., Kwiatkowski, C., Yuan, H., Kshirsagar, R., Ryll, T., & Huang, Y. (2014) · Biotechnology Progress · doi:10.1002/btpr.1884 · Cited by 156
Liu, B., Spearman, M. A., Doering, J., Lattová, E., Perreault, H., & Butler, M. (2013) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2013.11.007 · Cited by 141
Rameez, S., Mostafa, S. S., Miller, C., & Shukla, A. A. (2014) · Biotechnology Progress · doi:10.1002/btpr.1874 · Cited by 131
Lu, F., Toh, P. C., Burnett, I., Li, F., Hudson, T., Amanullah, A., & Li, J. (2012) · Biotechnology and Bioengineering · doi:10.1002/bit.24602 · Cited by 128
Povey, J. F., O'Malley, C. J., Root, T., Martin, E., Montague, G. A., Feary, M., Trim, C. M., Lang, D., Alldread, R. M., Racher, A. J., et al. (2014) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2014.04.028 · Cited by 59
Research works printed but not linked: 5
- Bioprocess Technology Consultants [Internet], 2014, bioTRAK® database
- Greb E, 2012, Pharmaceutical Technol, 36, 46
- Chollangi S, 2014, Bioprocess Int, 12, 48
- 10.12665/J124.Sha · doi:10.12665/j124.sha
- 10.2174/1566524053152898 · doi:10.2174/1566524053152898
Cited by
Aptamers as targeted therapeutics: current potential and challenges
Zhou, J., & Rossi, J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.199 · Cited by 2,221
Development of therapeutic antibodies for the treatment of diseases
Lu, R.-M., Hwang, Y.-C., Liu, I.-J., Lee, C.-C., Tsai, H.-Z., Li, H.-J., & Wu, H.-C. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0592-z · Cited by 2,085
Beyond binding: antibody effector functions in infectious diseases
Lu, L. L., Suscovich, T. J., Fortune, S. M., & Alter, G. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.106 · Cited by 825
Alternative molecular formats and therapeutic applications for bispecific antibodies
Spiess, C., Zhai, Q., & Carter, P. J. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.01.003 · Cited by 607
Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics
Bannas, P., Hambach, J., & Koch-Nolte, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01603 · Cited by 572
The Increasingly Human and Profitable Monoclonal Antibody Market
Grilo, A. L., & Mantalaris, A. (2019) · Trends in Biotechnology · doi:10.1016/j.tibtech.2018.05.014 · Cited by 462
Greenificated Molecularly Imprinted Materials for Advanced Applications
Ostovan, A., Arabi, M., Wang, Y., Li, J., Li, B., Wang, X., & Chen, L. (2022) · Advanced Materials · doi:10.1002/adma.202203154 · Cited by 442
Edmondson, S. D., Yang, B., & Fallan, C. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.04.030 · Cited by 422
Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins
Liu, L. (2018) · Protein & Cell · doi:10.1007/s13238-017-0408-4 · Cited by 390
Recent advances of PLGA micro/nanoparticles for the delivery of biomacromolecular therapeutics
Ding, D., & Zhu, Q. (2018) · Materials Science and Engineering: C · doi:10.1016/j.msec.2017.12.036 · Cited by 386
Shembekar, N., Chaipan, C., Utharala, R., & Merten, C. A. (2016) · Lab on a Chip · doi:10.1039/c6lc00249h · Cited by 372
IgG Fc engineering to modulate antibody effector functions
Wang, X., Mathieu, M., & Brezski, R. J. (2018) · Protein & Cell · doi:10.1007/s13238-017-0473-8 · Cited by 356
Therapies for rare diseases: therapeutic modalities, progress and challenges ahead
Tambuyzer, E., Vandendriessche, B., Austin, C. P., Brooks, P. J., Larsson, K., Miller Needleman, K. I., Valentine, J., Davies, K., Groft, S. C., Preti, R., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0049-9 · Cited by 357
Progress in biopharmaceutical development
Kesik‐Brodacka, M. (2018) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.1617 · Cited by 353
Phage display-derived human antibodies in clinical development and therapy
Frenzel, A., Schirrmann, T., & Hust, M. (2016) · mAbs · doi:10.1080/19420862.2016.1212149 · Cited by 346
Pereira, N. A., Chan, K. F., Lin, P. C., & Song, Z. (2018) · mAbs · doi:10.1080/19420862.2018.1466767 · Cited by 334
The state-of-play and future of antibody therapeutics
Elgundi, Z., Reslan, M., Cruz, E., Sifniotis, V., & Kayser, V. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.11.004 · Cited by 322
Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life
Saunders, K. O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01296 · Cited by 316
Immuno-Oncology: Emerging Targets and Combination Therapies
Marshall, H. T., & Djamgoz, M. B. A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00315 · Cited by 301
Affinity of human IgG subclasses to mouse Fc gamma receptors
Dekkers, G., Bentlage, A. E. H., Stegmann, T. C., Howie, H. L., Lissenberg-Thunnissen, S., Zimring, J., Rispens, T., & Vidarsson, G. (2017) · mAbs · doi:10.1080/19420862.2017.1323159 · Cited by 293
Vaisman-Mentesh, A., Gutierrez-Gonzalez, M., DeKosky, B. J., & Wine, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01951 · Cited by 292
Bispecific antibodies and their applications
Fan, G., Wang, Z., Hao, M., & Li, J. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0227-0 · Cited by 288
O’Flaherty, R., Bergin, A., Flampouri, E., Mota, L. M., Obaidi, I., Quigley, A., Xie, Y., & Butler, M. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2020.107552 · Cited by 277
Perfusion mammalian cell culture for recombinant protein manufacturing – A critical review
Bielser, J.-M., Wolf, M., Souquet, J., Broly, H., & Morbidelli, M. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.04.011 · Cited by 263
Fekete, S., Guillarme, D., Sandra, P., & Sandra, K. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.5b04561 · Cited by 258
David vs. Goliath: The Structure, Function, and Clinical Prospects of Antibody Fragments
Bates, A., & Power, C. A. (2019) · Antibodies · doi:10.3390/antib8020028 · Cited by 237
Predicting antibody developability profiles through early stage discovery screening
Bailly, M., Mieczkowski, C., Juan, V., Metwally, E., Tomazela, D., Baker, J., Uchida, M., Kofman, E., Raoufi, F., Motlagh, S., et al. (2020) · mAbs · doi:10.1080/19420862.2020.1743053 · Cited by 228
Camelid and shark single domain antibodies: Structural features and therapeutic potential
Könning, D., Zielonka, S., Grzeschik, J., Empting, M., Valldorf, B., Krah, S., Schröter, C., Sellmann, C., Hock, B., & Kolmar, H. (2017) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2016.10.019 · Cited by 214
How mRNA therapeutics are entering the monoclonal antibody field
Van Hoecke, L., & Roose, K. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1804-8 · Cited by 205
Drug permeability profiling using cell-free permeation tools: overview and applications
Berben, P., Bauer-Brandl, A., Brandl, M., Faller, B., Flaten, G. E., Jacobsen, A.-C., Brouwers, J., & Augustijns, P. (2018) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2018.04.016 · Cited by 199
abYsis: integrated antibody sequence and structure-management, analysis, and prediction
Swindells, M. B., Porter, C. T., Couch, M., Hurst, J., Abhinandan, K. R., Nielsen, J. H., Macindoe, G., Hetherington, J., & Martin, A. C. R. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.08.019 · Cited by 184
Fisher, A. C., Kamga, M.-H., Agarabi, C., Brorson, K., Lee, S. L., & Yoon, S. (2019) · Trends in Biotechnology · doi:10.1016/j.tibtech.2018.08.008 · Cited by 180
Capillary Electrophoresis Separations of Glycans
Lu, G., Crihfield, C. L., Gattu, S., Veltri, L. M., & Holland, L. A. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00669 · Cited by 174
Parapred: antibody paratope prediction using convolutional and recurrent neural networks
Liberis, E., Veličković, P., Sormanni, P., Vendruscolo, M., & Liò, P. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty305 · Cited by 165
A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy
Kong, D.-H., Kim, M., Jang, J., Na, H.-J., & Lee, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081786 · Cited by 161
Fornelli, L., Srzentić, K., Huguet, R., Mullen, C., Sharma, S., Zabrouskov, V., Fellers, R. T., Durbin, K. R., Compton, P. D., & Kelleher, N. L. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.8b00984 · Cited by 150
Dai, J., Lamp, J., Xia, Q., & Zhang, Y. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.7b04608 · Cited by 123
Humanization of antibodies using a machine learning approach on large-scale repertoire data
Marks, C., Hummer, A. M., Chin, M., & Deane, C. M. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btab434 · Cited by 124
“Therapeutic mAbs and antibody-related products such as Fc-fusion proteins, antibody fragments, nanobodies, and antibody-drug conjugates are now the predominant class of biopharmaceuticals, representing half the total sales of all biopharmaceutical products (2).”
BackgroundIn vitro and in silico assessment of the developability of a designed monoclonal antibody library
Wolf Pérez, A.-M., Sormanni, P., Andersen, J. S., Sakhnini, L. I., Rodriguez-Leon, I., Bjelke, J. R., Gajhede, A. J., De Maria, L., Otzen, D. E., Vendruscolo, M., et al. (2019) · mAbs · doi:10.1080/19420862.2018.1556082 · Cited by 97
sdAb-DB: the single domain antibody database
Wilton, E. E., Opyr, M. P., Kailasam, S., Kothe, R. F., & Wieden, H.-J. (2018) · ACS Synthetic Biology · doi:10.1021/acssynbio.8b00407 · Cited by 84
Chen, B., Lin, Z., Alpert, A. J., Fu, C., Zhang, Q., Pritts, W. A., & Ge, Y. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.8b01865 · Cited by 82
Jin, Y., Lin, Z., Xu, Q., Fu, C., Zhang, Z., Zhang, Q., Pritts, W. A., & Ge, Y. (2019) · mAbs · doi:10.1080/19420862.2018.1525253 · Cited by 68
Haselberg, R., De Vijlder, T., Heukers, R., Smit, M. J., Romijn, E. P., Somsen, G. W., & Domínguez-Vega, E. (2018) · Analytica Chimica Acta · doi:10.1016/j.aca.2018.08.024 · Cited by 64
Jain, T., Boland, T., Lilov, A., Burnina, I., Brown, M., Xu, Y., & Vásquez, M. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx519 · Cited by 61
Brown, A. J., Snapkov, I., Akbar, R., Pavlović, M., Miho, E., Sandve, G. K., & Greiff, V. (2019) · Molecular Systems Design & Engineering · doi:10.1039/c9me00071b · Cited by 59
Graham, R. J., Bhatia, H., & Yoon, S. (2019) · Biotechnology and Bioengineering · doi:10.1002/bit.27140 · Cited by 52
Innate Inspiration: Antifungal Peptides and Other Immunotherapeutics From the Host Immune Response
Mercer, D. K., & O'Neil, D. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02177 · Cited by 50
Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates
Dostalek, M., Prueksaritanont, T., & Kelley, R. F. (2017) · mAbs · doi:10.1080/19420862.2017.1323160 · Cited by 45
Continuous integrated manufacturing for biopharmaceuticals: A new paradigm or an empty promise?
Rathore, A. S., Thakur, G., & Kateja, N. (2023) · Biotechnology and Bioengineering · doi:10.1002/bit.28235 · Cited by 41
Liang, K., Luo, H., & Li, Q. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1112349 · Cited by 37
A two-step procedure for the design of perfusion bioreactors
Wolf, M. K. F., Pechlaner, A., Lorenz, V., Karst, D. J., Souquet, J., Broly, H., & Morbidelli, M. (2019) · Biochemical Engineering Journal · doi:10.1016/j.bej.2019.107295 · Cited by 32
Hogiri, T., Tamashima, H., Nishizawa, A., & Okamoto, M. (2018) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2017.08.015 · Cited by 30
Kozma, B., Salgó, A., & Gergely, S. (2018) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2018.06.005 · Cited by 27
Designing a Strategy for pH Control to Improve CHO Cell Productivity in Bioreactor
Ahleboot, Z., Khorshidtalab, M., Motahari, P., Mahboudi, R., Arjmand, R., Mokarizadeh, A., & Maleknia, S. (2021) · Avicenna Journal of Medical Biotechnology · doi:10.18502/ajmb.v13i3.6365 · Cited by 26
Monoclonal Antibodies: A Prospective and Retrospective View
Sivaccumar, J., Sandomenico, A., Vitagliano, L., & Ruvo, M. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867327666200219142231 · Cited by 14
Non-invasive real-time monitoring of cell concentration and viability using Doppler ultrasound.
Akbari, S., Anderson, P., Zang, H., Ganjian, A., Balke, R., Kwon, T., & Pollard, D. (2022) · SLAS technology · doi:10.1016/j.slast.2022.09.003 · Cited by 11
Metadata
- Authors
- Ecker, D. M., Jones, S. D., & Levine, H. L.
- Venue
- mAbs
- Publisher
- Informa UK Limited
- Published
- 2015-01-02
- Volume
- 7
- Issue
- 1
- Pages
- 9-14
- ISSN
- 1942-0862 (ISSN-L)
- 1942-0870
- OpenAlex
- W2094052190
- Cited by
- 1,286
- References
- 11
- FWCI
- 76.48
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.